ProCE Banner Activity

Defining Subsets of Patients in Early Breast Cancer in the Era of Precision Medicine

Slideset Download
Review the latest evidence on biomarkers defining clinically relevant subsets of patients with early breast cancer, including markers for endocrine therapy resistance, recurrence risk, and response predictive subtypes of TNBC and luminal B disease.

Released: December 07, 2022

Expiration: December 06, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

AstraZeneca Pharmaceuticals

Lilly

Merck Sharp & Dohme, LLC

Sanofi